Vivani Medical VANI Neurostimulation Division — D&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vivani Medical in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The official record: Vivani Medical’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vivani Medical's neurostimulation division — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Vivani Medical's neurostimulation division — D&A?
- Vivani Medical (VANI) reported neurostimulation division — D&A of $3.25K in Q4 2025.
- How has Vivani Medical's neurostimulation division — D&A changed year-over-year?
- Vivani Medical's neurostimulation division — D&A decreased by 56.7% year-over-year, from $7.5K to $3.25K.
- What is the long-term trend for Vivani Medical's neurostimulation division — D&A?
- Over 2 years (2023 to 2025), Vivani Medical's neurostimulation division — D&A has grown at a -45.6% compound annual growth rate (CAGR), from $44K to $13K.
- What does neurostimulation division — D&A mean?
- Represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the neurostimulation division. This metric reflects the wear and tear or obsolescence of the segment's capital equipment and technology portfolio. It is essential for understanding the true economic cost of maintaining the division's asset base.